Literature DB >> 19150344

Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance.

Ying Zhou1, Elizabeth Hopper-Borge, Tong Shen, Xiao-Cong Huang, Zhi Shi, Ye-Hong Kuang, Tatsuhiko Furukawa, Shin-Ichi Akiyama, Xing-Xiang Peng, Charles R Ashby, Xiang Chen, Gary D Kruh, Zhe-Sheng Chen.   

Abstract

Multidrug resistance protein 7 (MRP7; ABCC10) is an ABC transporter that confers resistance to anticancer agents such as the taxanes. We previously reported that several inhibitors of P-gp and MRP1 were able to inhibit the in vitro transport of E(2)17betaG by MRP7 in membrane vesicles transport assays. However, compounds that are able to reverse MRP7-mediated cellular resistance have not been identified. In this study, we examined the effects of cepharanthine (6',12'-dimethoxy-2,2'-dimethyl-6,7-[methylenebis(oxy)]oxyacanthan), an herbal extract isolated from Stephania cepharantha Hayata, to reverse paclitaxel resistance in MRP7-transfected HEK293 cells. Cepharanthine, at 2microM, completely reversed paclitaxel resistance in MRP7-transfected cells. In contrast, the effect of cepharanthine on the parental transfected cells was significantly less than that on the MRP7-transfected cells. In addition, cepharanthine significantly increased the accumulation of paclitaxel in MRP7-transfected cells almost to the level of control cells in the absence of cepharanthine. The efflux of paclitaxel from MRP7-transfected cells was also significantly inhibited by cepharanthine. The ability of cepharanthine to inhibit MRP7 was analyzed in membrane vesicle assays using E(2)17betaG, an established substrate of MRP7, as a probe. E(2)17betaG transport was competitively inhibited by cepharanthine with a K(i) value of 4.86microM. These findings indicate that cepharanthine reverses MRP7-mediated resistance to paclitaxel in a competitive manner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19150344     DOI: 10.1016/j.bcp.2008.12.005

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  30 in total

Review 1.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

2.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

3.  Cepharanthine exerts antitumor activity on choroidal melanoma by reactive oxygen species production and c-Jun N-terminal kinase activation.

Authors:  Qi Zhu; Baofeng Guo; Linlin Chen; Qiuye Ji; Hang Liang; Naiyan Wen; Ling Zhang
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

4.  Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Authors:  Neill J Liptrott; Sudeep Pushpakom; Christoph Wyen; Gerd Fätkenheuer; Christian Hoffmann; Stefan Mauss; Heribert Knechten; Norbert H Brockmeyer; Elizabeth Hopper-Borge; Marco Siccardi; David J Back; Saye H Khoo; Munir Pirmohamed; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

5.  Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.

Authors:  Ioana Abraham; Sandeep Jain; Chung-Pu Wu; Mohammad A Khanfar; Yehong Kuang; Chun-Ling Dai; Zhi Shi; Xiang Chen; Liwu Fu; Suresh V Ambudkar; Khalid El Sayed; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

6.  Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.

Authors:  Rishil J Kathawala; Kamlesh Sodani; Kang Chen; Atish Patel; Alaa H Abuznait; Nagaraju Anreddy; Yue-Li Sun; Amal Kaddoumi; Charles R Ashby; Zhe-Sheng Chen
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

7.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

8.  Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Authors:  Tong Shen; Ye-Hong Kuang; Charles R Ashby; Yu Lei; Angel Chen; Ying Zhou; Xiang Chen; Amit K Tiwari; Elizabeth Hopper-Borge; Jiangyong Ouyang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

9.  Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7).

Authors:  Ekaterina V Malofeeva; Natalya Domanitskaya; Mariya Gudima; Elizabeth A Hopper-Borge
Journal:  Cancer Res       Date:  2012-10-19       Impact factor: 12.701

10.  Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.

Authors:  Ye-Hong Kuang; Tong Shen; Xiang Chen; Kamlesh Sodani; Elizabeth Hopper-Borge; Amit K Tiwari; Jeferson W K K Lee; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2009-08-29       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.